WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

April 13, 2007 18:33 ET

WEX Receives Tianjin's Defence and Counterclaim

VANCOUVER, BRITISH COLUMIBA--(CCNMatthews - April 13, 2007) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) today announces that further to the Company's news release dated September 20, 2006 with regard to the legal proceedings brought against Tianjin Fairwood Mfg. Co. Ltd ("Tianjin") for the recovery of 2,598,425 WEX shares issued to Tianjin, some of which remain held in escrow, WEX recently received Tianjin's defence and counterclaim. In its statement of defence, Tianjin denied the claims alleged by the Company. The counterclaim by Tianjin seeks damages of $3,648,188 in respect of WEX's alleged failure to release shares still held in escrow, and other relief. The Company continues to believe that its claim is valid and consequently that Tianjin's counterclaim is without merit. WEX's legal action is proceeding.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward-Looking Statements and Information

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information